SG Americas Securities LLC acquired a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 28,631 shares of the company's stock, valued at approximately $773,000.
Several other large investors also recently made changes to their positions in the stock. Russell Investments Group Ltd. increased its position in shares of Janux Therapeutics by 77.7% during the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock worth $54,000 after acquiring an additional 442 shares in the last quarter. Avanza Fonder AB grew its position in Janux Therapeutics by 17.0% in the first quarter. Avanza Fonder AB now owns 3,049 shares of the company's stock valued at $86,000 after purchasing an additional 444 shares in the last quarter. Rhumbline Advisers grew its position in Janux Therapeutics by 1.6% in the fourth quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock valued at $2,043,000 after purchasing an additional 599 shares in the last quarter. Kennedy Capital Management LLC grew its position in Janux Therapeutics by 7.9% in the fourth quarter. Kennedy Capital Management LLC now owns 12,713 shares of the company's stock valued at $681,000 after purchasing an additional 928 shares in the last quarter. Finally, MetLife Investment Management LLC grew its position in Janux Therapeutics by 5.8% in the fourth quarter. MetLife Investment Management LLC now owns 17,298 shares of the company's stock valued at $926,000 after purchasing an additional 949 shares in the last quarter. Institutional investors own 75.39% of the company's stock.
Insider Activity at Janux Therapeutics
In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,333 shares of the firm's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $32.03, for a total value of $106,755.99. Following the sale, the insider now owns 82,139 shares in the company, valued at $2,630,912.17. This trade represents a 3.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 29.40% of the stock is currently owned by insiders.
Janux Therapeutics Price Performance
NASDAQ:JANX traded down $0.72 during mid-day trading on Monday, reaching $22.88. The stock had a trading volume of 620,000 shares, compared to its average volume of 866,181. The stock has a 50-day simple moving average of $26.55 and a two-hundred day simple moving average of $35.48. The stock has a market capitalization of $1.35 billion, a PE ratio of -16.82 and a beta of 2.97. Janux Therapeutics, Inc. has a 12 month low of $22.48 and a 12 month high of $71.71.
Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 9.29%. Equities analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.
Analysts Set New Price Targets
A number of research analysts recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 target price on shares of Janux Therapeutics in a research report on Monday, March 3rd. Scotiabank decreased their price objective on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research report on Friday, February 28th. Finally, Wedbush reissued an "outperform" rating and issued a $76.00 price objective (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $95.25.
Get Our Latest Stock Analysis on Janux Therapeutics
About Janux Therapeutics
(
Free Report)
Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Further Reading
Before you consider Janux Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Janux Therapeutics wasn't on the list.
While Janux Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
